Effects of anumigilimab, an anti-G-CSF receptor mAb, after segmental LPS challenge: A Phase 1b trial in healthy volunteers.
- DOI
- 10.1016/j.pupt.2026.102436
- Published
- 2026 Sep
- Container
- Pulmonary pharmacology & therapeutics
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.pupt.2026.102436,
title = {Effects of anumigilimab, an anti-G-CSF receptor mAb, after segmental LPS challenge: A Phase 1b trial in healthy volunteers.},
author = {Hohlfeld JM and Müller M and Badorrek P and Nicolas LB and Vit O and Darby WG and Field J and Larbig M},
year = {2026},
journal = {Pulmonary pharmacology \& therapeutics},
doi = {10.1016/j.pupt.2026.102436},
url = {https://doi.org/10.1016/j.pupt.2026.102436}
}RIS
TY - JOUR TI - Effects of anumigilimab, an anti-G-CSF receptor mAb, after segmental LPS challenge: A Phase 1b trial in healthy volunteers. AU - Hohlfeld JM AU - Müller M AU - Badorrek P AU - Nicolas LB AU - Vit O AU - Darby WG AU - Field J AU - Larbig M PY - 2026 JO - Pulmonary pharmacology & therapeutics DO - 10.1016/j.pupt.2026.102436 UR - https://doi.org/10.1016/j.pupt.2026.102436 ER -
APA
JM, H., M, M., P, B., LB, N., O, V., WG, D., J, F., & M, L. (2026). Effects of anumigilimab, an anti-G-CSF receptor mAb, after segmental LPS challenge: A Phase 1b trial in healthy volunteers.. Pulmonary pharmacology & therapeutics. https://doi.org/10.1016/j.pupt.2026.102436
Source records
- pubmed · retrieved 2026-09-26T19:10:50.645Z